Avid Bioservices Inc (CDMO)

[jakedogman1]

Key highlight of HALO earnings report..

"In February 2019, we announced that Genentech, a member of the Roche Group, received approval from the FDA for Herceptin Hylecta™, a co-formulation of trastuzumab and rHuPH20. Herceptin Hylecta™ is approved for the treatment of certain people with HER2-positive early breast cancer. Herceptin Hylecta™ is a ready-to-use formulation that can be administered in two to five minutes, compared to 30 to 90 minutes for intravenous trastuzumab. In April 2019, Roche made Herceptin Hylecta™ available in the U.S."

go back to the cdmo last cc regarding halo.....

and others working on ENHAZE.... things are getting interesting.... when will they need the extra capacity?